Safety and Efficacy of the Symetis ACURATE Neo/TF Compared to the Edwards SAPIEN 3 Bioprosthesis.

Insel Gruppe AG, University Hospital Bern739 enrolled

Overview

Transcatheter aortic valve implantation (TAVI) is an established treatment option for patients with severe symptomatic aortic stenosis and at increased risk for surgical aortic valve replacement (SAVR). Many novel devices are currently being developed and established transcatheter heart valves undergo design reiterations to address limitations and reduce complication rates associated with the device and implantation procedure. However, device comparisons by use of randomized trials are scarce in particular for newer generation transcatheter valves. The aim of this study is to assess non-inferiority of the self-expandable Symetis ACURATE neo/TF in comparison to the balloon-expandable Edwards SAPIEN 3 transcatheter aortic valve bioprosthesis with regard to early safety and clinical efficacy at 30 days.

Background: Transcatheter aortic valve implantation (TAVI) is an established and valuable treatment option for patients with severe symptomatic aortic stenosis and at increased risk for surgical aortic valve replacement (SAVR). The use of TAVI is rapidly expanding worldwide and the indications for TAVI are widening into lower risk populations in view of favorable outcomes among high and intermediate risk patients. Many novel devices are currently developed or established devices undergo design reiterations to address limitations, such as vascular access complications, paravalvular regurgitation, and atrio-ventricular conductance disturbances. However, device comparisons by use of randomized trials are scarce in particular for newer generation transcatheter valves. The Symetis ACURATE neo/TF, a self-expandable transcatheter valve delivered via transfemoral access, gained Conformité Européenne (CE) marking in September 2014 after showing favorable procedural and short term results. The SCOPE I trial will compare its performance to the balloon-expandable Edwards SAPIEN 3, a widely used and well-established transcatheter heart valve of the second generation, in a randomized fashion. Objectives: The primary objective is the comparison of the Symetis ACURATE neo/TF to the Edwards SAPIEN 3 transcatheter aortic bioprosthesis with regard to early safety and clinical efficacy at 30 days. Secondary objectives involve the comparison between the two devices with regard to secondary clinical and echocardiographic endpoints at 30 days, 1 year and 3 years. Methods: Sample Size: Based on an anticipated incidence proportion of 22% for the primary non-hierarchical composite endpoint at 30 days in both treatment arms, a non-inferiority margin of 7.7%, a power of 80%, a one-tailed significance level of α = 0.05, and a low attrition rate, the total required sample size amounts to 730 patients. Design: Patients will be allocated to the Symetis ACURATE neo/TF or the Edwards SAPIEN 3 bioprosthesis at a 1:1 ratio by means of a randomly permuted block randomisation stratified on study center and Society of Thoracic Surgeons' predicted risk of mortality score (STS-PROM) strata (\< 3%, ≥ 3 to \< 8%, ≥ 8%). Analysis: Estimates of the risk-differences between the two treatment arms with regard to the primary endpoint will be pooled over the predefined STS-PROM strata by means of the Cochran-Mantel-Haenszel method and Wald-type confidence limits will be calculated using the Sato variance estimator. The non-inferiority assumption will be tested at a one-sided significance level with a type I error rate (α) = 0.05. The analysis of the primary composite endpoint will be conducted according to the intention-to-treat (ITT) and the per protocol (PP) principle and non-inferiority should be claimed only if met by both. In case non-inferiority is established, a superiority analysis will be performed using a two-tailed significance level with a type I error rate of α = 0.05. Further secondary analyses will evaluate between group differences in relation to demographic, clinical, procedural, functional and imaging characteristics. Pre-specified subgroup analyses will be conducted by use of appropriate interaction tests contrasting categories of sex, STS-PROM score (\< 3%, ≥ 3 to \< 8%, ≥ 8%), left ventricular ejection fraction (\< 50% vs. ≥ 50%), and native aortic valve eccentricity index (≤ 0.25 vs. \> 0.25).

Eligibility

Sex: ALLMin age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with severe aortic stenosis defined by an aortic valve area (AVA) \< 1cm2 or AVA indexed to body surface area (BSA) of \< 0.6 cm2/m2, including low-flow severe aortic stenosis defined by stroke volume index (SVI) \< 35ml/m2, as assessed by integration of echocardiographic and invasive measurements * Subject is symptomatic (heart failure symptoms with New York Heart Association (NYHA) Functional Class \> I, angina or syncope) * Patient is considered at increased risk for mortality if undergoing conventional surgical aortic valve replacement or judged as not operable as determined either * by a Logistic EuroSCORE \> 20 % OR * by a STS-PROM score \> 10% OR * by the heart team consisting of at least one cardiologist and cardiac surgeon based on the integration of individual clinical and anatomical factors not captured by risk-scores, the patient's age, frailty and life-expectancy * The heart team agrees on eligibility of the patient for participation and that TAVI by transfemoral access constitutes the most appropriate treatment modality, from which the patient will likely benefit most * Aortic annulus dimensions suitable for both valve types (area range: 338-573 mm2 AND perimeter range: 66-85 mm) based on ECG-gated multislice computed tomographic measurements. Findings of transesophageal echocardiography (TEE) and conventional aortography should be integrated in the anatomic assessment if available * Arterial aorto-iliac-femoral axis suitable for transfemoral access with a minimum access vessel diameter ≥ 6 mm as assessed by multislice computed tomographic angiography and/or conventional angiography * Written informed consent of the patient or her/his legal representative * Patient understands the purpose, the potential risks as well as benefits of the trial and is willing to participate in all parts of the follow-up Exclusion Criteria: * Non-valvular aortic stenosis * Congenital aortic stenosis or unicuspid or bicuspid aortic valve * Non-calcific acquired aortic stenosis * Anatomy not appropriate for transfemoral transcatheter aortic valve implantation due to size of the aortic annulus or degree or eccentricity of calcification of the native aortic valve or tortuosity of the aorta or ilio-femoral arteries * Emergency procedure including patients in cardiogenic shock (low cardiac output, vasopressor dependence, mechanical hemodynamic support) * Severely reduced left ventricular (LV) function (ejection fraction \< 20%) * Pre-existing prosthetic heart valve in aortic position * Presence of mitral valve prosthesis * Concomitant planned procedure except for percutaneous coronary intervention (PCI) * Planned non-cardiac surgery within 30 days * Stroke within 30 days of the procedure. * Myocardial infarction within 30 days of the procedure (except type 2) * Evidence of intra-cardiac mass, thrombus or vegetation * Severe coagulation conditions * Inability to tolerate anticoagulation/anti-platelet therapy * Active bacterial endocarditis or other active infections * Hypertrophic cardiomyopathy with or without obstruction * Contraindication to contrast media or allergy to nitinol * Participation in another trial, which would lead to deviations in the preparation or performance of the intervention or the post-implantation management from this protocol

Locations (20)

Herz- und Gefäss-Klinik GmbH Bad Neustadt

Bad Neustadt an der Saale, Bad Neustadt, Germany

Klinkum Augsburg

Augsburg, Germany

Zentralklinik Bad Berka

Bad Berka, Germany

Herz- und Gefässzentrum Bad Beversen

Bad Bevensen, Germany

Kerckhoff-Klinik

Bad Nauheim, Germany

Herzzentrum Uniklinik Köln

Cologne, Germany

St.-Johannes-Hospital

Dortmund, Germany

Herzzentrum Dresden

Dresden, Germany

Universitäres Herzzentrum Hamburg GmbH

Hamburg, Germany

Städtisches Klinikum Karlsruhe

Karlsruhe, Germany

...and 10 more locations

Outcomes

Primary Outcomes

Modified* combined early safety and clinical efficacy as defined by the Valve Academic Research Consortium-2 (VARC-2)

(\* "NYHA class III or IV" is omitted due to lack of objectiveness in its ascertainment) * All-cause mortality * All stroke (disabling and non-disabling) * Life-threatening or disabling bleeding * Acute kidney injury (stage 2 or 3, including renal replacement therapy) * Coronary artery obstruction requiring intervention * Major vascular complication * Valve related dysfunction requiring repeat procedure (balloon aortic valvuloplasty, TAVI or SAVR in a separate intervention) * Rehospitalization for valve-related symptoms or worsening congestive heart failure * Valve-related dysfunction: prosthetic aortic valve stenosis (mean gradient ≥ 20 mmHg, effective orifice area ≤ 0.9-1.1cm2 and/or Doppler velocity index \< 0.35) AND/OR ≥ moderate prosthetic valve regurgitation)

Time frame: 30 days

Secondary Outcomes

Device success

Combined endpoint composed of: * Absence of procedural mortality AND * Correct positioning of a single prosthetic heart valve into the proper anatomical location AND * Intended performance of the prosthetic heart valve (no prosthesis-patient mismatch and mean aortic valve gradient \< 20 mmHg or peak velocity \< 3 m/s, AND no moderate or severe prosthetic valve regurgitation)

Time frame: 30 days

Early safety

Combined endpoint composed of: * All-cause mortality * All stroke (disabling and non-disabling) * Life-threatening or disabling bleeding * Acute kidney injury - stage 2 or 3 (including renal replacement therapy) * Coronary artery obstruction requiring intervention * Major vascular complication * Valve-related dysfunction requiring repeat procedure (balloon aortic valvuloplasty, TAVI, or SAVR)

Time frame: 30 days

Clinical efficacy

Combined endpoint composed of: * All-cause mortality * All stroke (disabling and non-disabling) * Requiring hospitalizations for valve-related symptoms or worsening congestive heart failure * NYHA class III or IV * Valve-related dysfunction (mean aortic valve gradient ≥ 20 mmHg, effective orifice area (EOA) ≤ 0.9-1.1 cm2 and/or Doppler velocity index (DVI) \< 0. 35 m/s, AND/OR moderate or severe prosthetic valve regurgitation)

Time frame: 30 days

Time-related valve safety

Combined endpoint composed of: * Structural valve deterioration (Valve-related dysfunction (mean aortic valve gradient ≥ 20 mmHg, EOA ≤ 0.9-1.1 cm2 (depending on body surface area (BSA)) and/or DVI \< 0.35 m/s AND/OR moderate or severe prosthetic valve regurgitation)) OR Requiring repeat procedure (TAVI or SAVR) * Prosthetic valve endocarditis * Prosthetic valve thrombosis * Thrombo-embolic events (e.g. stroke) * VARC bleeding, unless clearly unrelated to valve therapy (e.g. trauma)

Time frame: 30 days, 1 year

All-cause mortality